Lenalidomide

Drug Profile

Lenalidomide

Alternative Names: CC-5013; CDC-501; CDC-5013; ENMD-0997; IMiD-1; IMiD-3; Ladevina; Revlimid

Latest Information Update: 19 Apr 2017

Price : $50

At a glance

  • Originator Celgene Corporation
  • Developer Baylor College of Medicine; Celgene Corporation; Dana-Farber Cancer Institute; H. Lee Moffitt Cancer Center and Research Institute; Indiana University School of Medicine; IRCCS San Raffaele; National Cancer Institute (USA); Novartis; Ohio State University Comprehensive Cancer Center; Roche; Roswell Park Cancer Institute; SCRI Development Innovations; University of Florida; Washington University School of Medicine
  • Class 2 ring heterocyclic compounds; Antineoplastics; Imides; Isoindoles; Piperidones; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Immunomodulators; Interleukin 1 beta inhibitors; Interleukin 10 stimulants; Interleukin 2 receptor modulators; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma; Myelodysplastic syndromes; Chronic lymphocytic leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Mantle-cell lymphoma; Multiple myeloma; Myelodysplastic syndromes
  • Preregistration Adult T-cell leukaemia-lymphoma
  • Phase III Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
  • Phase II Acute myeloid leukaemia; Histiocytosis; Hodgkin's disease
  • Phase I/II Non-small cell lung cancer
  • Phase I Cancer; Chronic myeloid leukaemia; Peripheral T-cell lymphoma
  • No development reported Eye neoplasms; Glioblastoma; Myelofibrosis; Prostate cancer
  • Discontinued Colorectal cancer; Heart failure; Hepatocellular carcinoma; Inflammation; Malignant melanoma

Most Recent Events

  • 29 Mar 2017 Phase-I/II clinical trials in Non-small cell lung cancer (Combination therapy, Second-line therapy or greater) in USA (PO) (NCT02963610)
  • 03 Mar 2017 Launched for Multiple myeloma (Combination therapy, Second-line therapy or greater) in Iceland (PO)
  • 03 Mar 2017 Launched for Multiple myeloma (First-line therapy, Newly diagnosed) in Iceland (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top